Results 231 to 240 of about 573,431 (299)

The National Academies’ 2024 Diagnostic Criteria for Long COVID: Concerns That Could Affect the Rheumatology Community

Arthritis &Rheumatology, EarlyView.
Leonard H. Calabrese, Michael Putman, Jeffrey A. Sparks, Zachary Wallace, Alfred H. J. Kim, Kevin L. Winthrop, Cassandra Calabrese   +6 more
wiley   +1 more source

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

Arthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Gout and rheumatoid arthritis are associated with subclinical vascular damage, reduced brachial vasoreactivity and coronary microvascular dysfunction: a case-control study. [PDF]

Rheumatol Int
Konal O, Bölen F, Güvenç TS, Pehlivan Ö, Batıbay S, Özcan FB, Paralı A, Aksu F, Kul Ş, Çalışkan M.   +9 more
europepmc   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

Arthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Imaging of Peripheral Arthritis: Special Focus on Differences in Inflammatory Lesions Between Rheumatoid Arthritis and Psoriatic Arthritis. [PDF]

Korean J Radiol
Fukuda T, Ogihara A, Kisaki S, Momose M, Umezawa Y, Asahina A, Ojiri H.   +6 more
europepmc   +1 more source

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

RETRACTION: lncRNA BZRAP1-AS1 Alleviates Rheumatoid Arthritis by Regulating miR-1286/COL5A2 Axis. [PDF]

Immun Inflamm Dis
europepmc   +1 more source

Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. [PDF]

Front Med (Lausanne)
Martinez-Molina C, Vidal S, Diaz-Torne C, Park HS, Corominas H.   +4 more
europepmc   +1 more source

Comparative Analysis of Circulating and Synovial Immune Cells in Early Untreated Rheumatoid Arthritis and their relationship with molecular pathology and disease outcomes

Arthritis &Rheumatology, Accepted Article.
Objectives To assess the relationship of circulating and synovial immune cells with synovial molecular pathology and disease outcomes in early Rheumatoid Arthritis (RA). Methods Early (<12 months) treatment‐naïve RA patients (n=144) from the Pathobiology of Early Arthritis Cohort (PEAC) were included in this posthoc analysis.
Felice Rivellese, Elena Pontarini, Liliane Fossati‐Jimack, Rita A. Moura, Vasco C. Romão, João Eurico Fonseca, Alessandra Nerviani, Cankut Çubuk, Katriona Goldmann, Giovanni Giorli, Myles Lewis, Michele Bombardieri, Costantino Pitzalis, Pathobiology of Early Arthritis Cohort (PEAC) investigators   +13 more
wiley   +1 more source